Is cloud the answer to healthcare industry’s challenges?

Healthcare providers foresee transformational cloud-based models emerging in the near future

04-Oct-2013 - Healthcare regimes all over the world are in crisis fighting diverse challenges including rising healthcare costs, aging populations, dynamic burden of diseases and increasing demand for accountable care. In response to these challenges healthcare stakeholders seek innovative technologies that ...

Open Source Innovation Is Increasingly Being Used to Promote Innovation in the Drug Discovery Process and Boost Bottom Lines

23-Nov-2010 - The completion of the human genome project generated a plethora of complex information that launched the medical community into the next era of therapeutic intervention. New discoveries have led to the need for new ways to tap the vast amounts of information, so as to optimise its potential use. ...

Early Screening, Innovative Solutions to Underline Importance of ADME/Tox Technologies in Successful Drug Development

Considerable Time, Cost Savings to Accrue from Advanced ADME/Tox Technologies

10-Aug-2005 - Typically, new drug approval is a protracted, expensive and complex process. Approximately 90 per cent of clinical candidates fail during the development stage with the estimated costs due to poor absorption, distribution, metabolism, elimination (ADME) or toxicity properties itself pegged at ...

New Drug Delivery Techniques Aim to Improve Overall Drug Performance and Efficacy

15-Mar-2005 - Quantum leaps made in the field of proteomics, genomics and biotechnology are creating revolutionary therapeutics that require equally impressive drug delivery systems in order for patients to derive optimum benefits. This, coupled with patent expirations and subsequent competitive threats from ...

Opportunities for European Pharmaceutical and Biotechnology Companies in Indian and Chinese

09-Mar-2005 - Despite having over a third of the world's population, Asia accounts for only one fifth of global pharmaceutical drug consumption. As income levels rise, demand from this large population base is set to burgeon, opening up new growth opportunities for pharmaceutical and biotechnology companies. ...

Frost: Strategic Analysis of the Opportunities for the Pharmaceutical and Biotechnology Industry in the 'New' EU Countries

Pharmaceutical and Biotechnology Industry in the 'New' EU Countries Presents Considerable Potential, Parallel Imports Remain a Challenge

25-Feb-2005 - In contrast to subdued growth in the pharmaceutical markets of the former 15-state European Union (EU), pharmaceutical markets in the 'new' EU accession markets are expanding vibrantly. While the former has been increasing at eight per cent annually, the latter has been growing at the rate of ...

Frost & Sullivan: Escalating Demand for Novel and Effective Therapeutic Approaches Underlines Growing Appeal of Peptides

Strategic Analysis of the Therapeutic Peptides Market in Europe

14-Jan-2005 - With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is ...

Strategic Analysis of European High Throughput Screening Market

01-Nov-2004 - Pharmaceuticals and biotechnology companies are under constant pressure to discover and develop new therapeutics at a lesser cost and within shorter timeframes. However, with investments exceeding USD 500 million and nine out of ten candidates failing to get drug approval, pharmaceuticals and ...

Strategic Analysis of the World Oligonucleotides Markets

Innovation Integral to Increased Adoption of Oligonucleotide Technologies

01-Aug-2004 - London, UK. Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan (http://pharma.frost.com) estimates that the total global market for oligonucleotides is likely to grow from ...

Drug Discovery Companies Focus on Strong Product Line to Offset R&D Budget Slowdown

20-Feb-2004 - One of the most persistent challenges facing manufacturers and distributors of research products is the slowed growth of R&D spending for all segments of the drug discovery market. While pharmaceutical companies are affected by slow top line growth, biotechs need to become more product-oriented, ...